GIGABYTE
5.1.2023 19:01:39 CET | Business Wire | Press release
GIGABYTE, a leading supplier of computer hardware and pioneer in the tech industry, presents “Power of Computing” at CES 2023 to demonstrate exceptional computing prowess that drives innovative technologies forward. An extensive range of enterprise and personal computer solutions are brought to the show to resonate with the theme.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230105005713/en/
GIGABYTE at CES 2023: Power of Computing to Reshape the World (Photo: Business Wire)
- Data Center Servers: Computing breakthroughs that propel next-gen technologies and AI applications.
- Advanced Cooling Solutions: Computing performance and environmental sustainability in harmony.
- Mobile Computing Platforms: Zonal computing to enable a safer and greener transportation.
- PCs and Laptops: Next-gen performance delivered for digital natives.
Data Center is an integral part of making technological breakthroughs. GIGABYTE has always been trusted as a pioneer in developing new server products for developers, and worked on software integrations to provide product solutions that are in line with the future of the digital age. GIGABYTE brought to CES its next-gen server hardware and computing technology that unleashes greater performance, improved energy efficiency, and is ready for high-density compute with the latest CPUs and GPUs to accelerate workloads of any scale. Also showcased is an enterprise-grade workstation that coupled with MyelinTek’s ready-to-go MLOps AI development environment. The MLOps’s easy-to-use interface enables engineers to quickly train AI models suited for their innovations, and the workstation’s outstanding performance allows a painless implementation.
Computing demands are facing a thermal dilemma in which performance gain is at environment’s sacrifice. GIGABYTE’s Air, Liquid, and Immersion Cooling Solutions are specially designed to increase heat dissipation efficiency, empowering servers to deliver exceptional high performance while lowering carbon emissions, paving the way for a sustainable future without sacrificing economic growth. At its CES booth GIGABYTE also debuts TO15-Z40, which is an OCP server compatible with all major immersion tanks, to show the most future-proof computing to industry leaders who wish to create a balance in tech advancements and environmental sustainability.
Vehicle tech is thriving as it leverages the power of computing to helm artificial intelligence and communications, therefore paving way for safer driving and smarter traffic. With extensive experience in developing ADCU (Autonomous Driving Control Unit) and ADAS DCU (Domain Control Unit), GIGABYTE provides the automotive industry with high-performance Zonal Integrated DCUs and decision-making control hosts, which are built with a centralized architecture and can be integrated into various requirements and design concepts, lowering vehicle production costs.
GIGABYTE launched its newest iteration of AERO creator laptops and AORUS gaming laptops just in time before CES begins. Both laptops series are built with 13th gen Intel® Core™ processors and NVIDIA RTX™ 40 series graphics cards, and in addition, are designed with the latest technologies, to present tech fanatics with computing performance that exceeds their expectations. The newly crowned CES 2023 Innovation Award winner, Stealth 500 PC DIY Kit, and a whopping 48” gaming monitor are also showcased for users to feast their eyes on.
Visit GIGABYTE ‘Power of Computing’ event page
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005713/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom